Stockreport

Taysha Gene Therapies Regains Full Global Rights to Lead Rett Syndrome Program TSHA-102 [Yahoo! Finance]

Taysha Gene Therapies, Inc.  (TSHA) 
PDF announced that it had regained full global rights to its lead program, TSHA-102, which is in clinical evaluation for the treatment of Rett syndrome. The 2022 Option Agre [Read more]